---
schema_version: "secwatch.filing_event.v1"
accession: "0001439222-23-000117"
form_type: "8-K"
ticker: "AGIO"
cik: "0001439222"
company_name: "AGIOS PHARMACEUTICALS, INC."
filed_at: "2023-08-03T23:59:59+00:00"
generated_at: "2026-06-12T07:47:33.203851+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Agios Q2 2023: PYRUKYND revenue $6.7M; net loss $83.8M; pipeline advances

## Summary
- PYRUKYND net revenue $6.7M in Q2, up 20% QoQ; 147 patients completed enrollment forms, 99 on therapy.
- Net loss $83.8M vs $91.8M a year ago; cash $946.9M, expected runway into 2026.
- Phase 2 mitapivat in sickle cell positive; Phase 3 enrollment to begin Q4 2023.
- Completed enrollment in Phase 3 thalassemia studies (ENERGIZE/ENERGIZE-T) and Phase 2a AG-946 in LR-MDS.
- Licensed Alnylam siRNA for polycythemia vera; appointed Catherine Owens to board.

## SEC filing metadata
- accession: 0001439222-23-000117
- form_type: 8-K
- ticker: AGIO
- cik: 0001439222
- company_name: AGIOS PHARMACEUTICALS, INC.
- filed_at: 2023-08-03T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1439222/000143922223000117/0001439222-23-000117-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1439222/000143922223000117/agio-20230803.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001439222-23-000117
- JSON: https://secwatch.observer/filing/0001439222-23-000117.json
- Plain text: https://secwatch.observer/filing/0001439222-23-000117.txt

## Key facts
- Earnings Releases
  AGIOS PHARMACEUTICALS, INC. reported the second quarter ended June 30, 2023 results: revenue $6.7 million, net income $83.8 million.
  - Period: the second quarter ended June 30, 2023
  - Revenue: $6.7 million
  - Net income: $83.8 million
  - Result: reported results
  source text: License Agreement with Alnylam Pharmaceuticals to License Alnylam’s Novel siRNA for the Potential Treatment of Polycythemia Vera – U.S. PYRUKYND ® (mitapivat) Net Revenue of $6.7 Million in Q2; $947 Million of Cash, Cash Equivalents and Marketable Securities as of June 30, 2023 CAMBRIDGE, Mass., August 3, 2023 -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a
  evidence_url: https://www.sec.gov/Archives/edgar/data/1439222/000143922223000117/0001439222-23-000117-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.